论文部分内容阅读
目的探讨原发性肝癌伴有门脉癌栓肝动脉化疗栓塞术(TACE)治疗的安全性及疗效。方法收集2006年1月至2011年1月在我院行TACE治疗的120例原发性肝癌患者,对其进行回顾性分析研究。术前常规CT增强检查确定门脉癌栓情况,将其分为:无门脉癌栓、主干癌栓、左支癌栓、右支癌栓四组,Kaplan-Meier法计算累计生存率及各组中位生存时间,Log-rank检验方法检验。结果总体6个月、1、2、3年累积生存率为:92%、67%、35%、22%。中位生存时间为19.16个月。无门静脉癌栓患者占65.00%(78/120)、左支癌栓患者占4.17%(5/120)例、右支癌栓患者占23.33%(28/120)及主干癌栓患者占7.50%(9/120)例,各组中位生存期分别为22、12、15、8个月,均大于半年。结论肝动脉化疗栓塞治疗伴门脉癌栓的原发性肝癌,是一种安全有效的方法,能明显延长患者生存时间。
Objective To investigate the safety and efficacy of transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer. Methods A total of 120 patients with primary hepatocellular carcinoma treated with TACE in our hospital from January 2006 to January 2011 were retrospectively analyzed. Preoperative routine CT enhanced examination to determine portal vein thrombosis, will be divided into: portal vein tumor thrombus, main tumor thrombus, left branch tumor thrombus, right branch cancer thrombus four groups, Kaplan-Meier method to calculate the cumulative survival rate and Group median survival time, Log-rank test method test. Results Overall 6 months, 1, 2, 3 years cumulative survival rate: 92%, 67%, 35%, 22%. The median survival time was 19.16 months. Patients with portal vein thrombosis accounted for 65.00% (78/120), patients with thrombolysis of the left branch thrombosed in 4.17% (5/120), patients with right branch thrombus (23.33% (28/120)) and patients with primary tumor thrombus (7.50% (9/120) cases, the median survival of each group were 22,12,15,8 months, were greater than six months. Conclusion Transcatheter arterial chemoembolization in the treatment of primary hepatocellular carcinoma with portal vein tumor thrombus is a safe and effective method to prolong the survival time of patients.